10x Genomics Lifts 2026 Sales Outlook To $625 Million–$635 Million As Quarterly Loss Narrows
Consumables sales increased while instrument revenue fell, and lower inventory markdowns helped improve gross margin.
10x Genomics, which makes instruments, consumables and software for single-cell and tissue research, raised its 2026 revenue outlook Thursday to $625 million–$635 million, from $610 million–$630 million, according to its earnings release accompanying an SEC filing. Third-quarter sales rose 1%, but lower costs and a changed product mix produced a larger improvement in its losses.
Consumables Grow, Instrument Sales Fall
Quarterly revenue reached $150.7 million, compared with $149.0 million a year earlier. TXG shares rose about 2% to $59.30 in Friday trading.
Consumables brought in $134.327 million, versus $127.892 million a year earlier. Within that business, products used to map biology within tissue generated $41.188 million, compared with $35.373 million; single-cell consumables generated $93.139 million, versus $92.519 million.
Instrument revenue moved the other way, falling to $6.858 million from $11.999 million. Services revenue increased to $9.025 million from $8.128 million.
The annual outlook carries an important distinction: management expects growth of 4%–6% when non-recurring patent-settlement license and royalty revenue is excluded from both 2026 and 2025. For the first nine months, total revenue was $452.546 million versus $476.793 million, while products and services revenue increased to $449.200 million from $430.999 million.
Lower Markdowns Improve Gross Margin
The company retained 75% of sales after product and service costs, up from 67% a year earlier. Management attributed the improvement mainly to smaller inventory markdowns and the mix of products sold.
Operating expenses fell 3% to $129.0 million from $132.5 million. Reduced personnel and laboratory-equipment spending outweighed an increase in litigation costs.
The operating loss narrowed to $16.1 million from $32.2 million. The net loss also shrank, to $19.4 million from $27.5 million, with the per-share loss declining to $0.15 from $0.22.
Atera Ships, Sentira Adds AI Analysis
The business serves academic and government researchers as well as biopharmaceutical and biotechnology institutions. Its Chromium platform examines individual cells; Visium and Xenium help researchers locate molecules within tissue.
10x began worldwide commercial shipments of Atera and introduced Sentira, a cloud-based tool for analyzing biological datasets. Sentira uses NVIDIA computing to process spatial data and Anthropic’s Claude for AI analysis of single-cell data.
Serge Saxonov, co-founder and CEO of 10x Genomics, connected broader business results to consumables: “We were also encouraged with the results across our broader business, driven by continued strength in consumables.”
10x ended September with $575.7 million in cash, cash equivalents and marketable securities, alongside a smaller quarterly operating loss.
Sources
- 8-K Filing — 10x Genomics, Inc. (TXG) — SEC EDGAR
- Exhibit txg-20261105xexx991.htm — 10x Genomics, Inc. 8-K exhibit — SEC EDGAR
- 10x Genomics: Q3 Earnings Snapshot | 9news.com — Associated Press
- 10x Genomics Reports Third Quarter 2026 Financial Results — prnewswire.com